The FDA has approved a new drug called Ocrevus (ocrelizumab) for adults with relapsing forms of multiple sclerosis (MS) and primary progressive MS (PPMS). This is the first treatment ever approved for PPMS, a form of MS that steadily worsens over time. Ocrevus works by targeting and depleting certain immune cells (B cells) that are thought to damage the nervous system in MS.
Ocrevus is given as an infusion into a vein. Before starting treatment, patients need blood tests to check for hepatitis B, measure immunoglobulin levels, and assess liver function. To reduce the risk of infusion reactions, patients receive premedication with corticosteroids and antihistamines.
This approval offers a new option for people with active MS, including those with progressive forms. However, it is not a cure. Patients should talk to their doctor to see if Ocrevus is right for them, considering their specific type of MS and overall health.